Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs

Anemia in CKD is associated with increased risk of CKD progression, poor CV outcomes, decreased health-related quality of life, and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Share

Program Content

Activities

  • Lowering the Burden of Anemia in CKD
    Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2022

    Expires: December 19, 2023

Provided by

ProCE Banner
ProCE Banner

Jointly provided by USFH and Rockpointe.

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline